FHUADAPT ADdiction And Psychiatry TRANSFORMATION thanks to Precision Medicine

Marion Leboyer

AP-HP, DMU IMPACT, Mondor Hospital, Créteil **INSERM** U 955, IMRB, Translational NeuroPsychiatry lab, University Paris-Est-Créteil (UPEC) CEO Fondation FondaMental

Philippe Vernier Director, Neurosciences (Neuro-Psi) & Life Sciences Institutes **CEA**, Saclay


Jean-François Mangin Information Processing Unit, Neurospin, **CEA**, Saclay



MENTAL DISORDERS: a major public health issue in great need of innovation to improve prognosis and to reduce costs

Worldwide


- The world's leading cause of handicap by 2020 according to the WHO¹
- 38% of 18-65 year old Europeans are affected by a mental disorder
- First cause of DALYS (Disability adjusted Life): 20.6%



¹Murray and Lopez, Science, 1996; WHO, European status on alcohol and health, 2001

In France

- 12 millions of French citizens affected by a mental disorder
- Total direct and indirect cost²: €109Bn per year
- First cause of health Insurance expenditures due to chronic disorders: €22.5Bn




THE CHALLENGE: To break up heterogeneity of major psychiatric disorders

Heterogeneity is hindering research: non-replication of results Heterogeneity is hindering treatment : small effect size

> ONE SIZE DOES'NT FIT ALL



OUR VISION: Precision Medicine will transform diagnosis, treatment and prognosis of patients with mental disorders



A PROJECT BUILT ON TRACK RECORDS obtained within previous projects (AP-HP, PIA2)




FHU ADAPT is built on track records of results obtained within

- DHU Pe-PSY (AP-HP PI M Leboyer)
- Psy-COHort (PI M Leboyer) and LABEX Bio-Psy (PI JA Girault and *M Leboyer*), Programme Investissement d'Avenir

Preliminary results to develop Precision Medicine

- Brain and peripheral biomarkers: Genetic and Environment risk • factors, Immunology, Metagenomic, Brain imaging ...
- **Apps, Plateforms:** Digital phenotyping to enable continuous real life, objective, quantitative phenotype
- **Big data/machine learning:** Algorithms to diagnose and predict prognosis
- Neuromodulation: Invasive/non invasive brain stimulation

Machine Learning applied to MRI in Schizophrenia De Pierrefeu et al. 2018



Vertex-based cortical features


Auto-immune psychosis

Pollack et al, Lancet Psy, 2019


Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of

suspected autoimmune origin

GWAS meta-analysis in Bipolar Disorder, Schizophrenia, Autism Spectrum disorder PGC. Lancet 2013



NK Cells activation in Autism Bennabi et al, 2019, Mol Autism



Environmental risk factors in psychosis Pignon et al, Science Rep, 2017





Deep Brain Stimulation in OCD Mallet et al, NEJM, 2008 & 2019



FHU ADAPT, linking psychiatry/addictology departments (DMU IMPACT, AP-HP) with public and private research within the Grand-Paris Sud region ASSISTANCE HÔPITAUX \mathbf{b} PUBLIQUE **DE PARIS Neurospin Institute IRS Center for Data** Population Number of Along the AP-HP DMU IMPACT researchers: size: **Psychiatry-addictology** 5 M 245 of the Grand Paris Sud O st-Denis • Hal Henri Mondor, Créteil Plevel CHIC, Créteil 0 • Hal Paul Brousse, Villejuif La Défense Neuroimaging facility Data Management, Hal Kremlin-Bicêtre, 3; 7; 11.7 Tesla Statistics, Machine Learning, • Hal Mignot, **Versailles** (pre-clinical 17 Tesla) Design of e-health services • Hal Barthelemy Durand, **Etampes** Paris • Hal Orsay, Orsay NeuroPsi Institute A13 **PLATFORMS** Versailles Issy RER Grand Parc CEA, Neurospin N 118 CEA, Genomic National Center Versai **A**A Arcueil-Cachan/O O Villejuif 0 CEA. Metabohub O Créteil A Les Ardoine Inserm, Pollurisk (IMRB) A86 Saint-Quentin en-Yvelines INSTITUTE **RN10** Pont de Rungis 17 research teams dedicated to INRIA, Data Science Massy preclinical research on CNS INRA, Metagenopolis 0 占 functions in a new building of N CEA, Neuro-Psi 12000 m², Opening: 2020 International Airport (REP) (B) 0-Inserm, Institut du Fer à Moulin with 340 staff Paris-Saclay A10 Ĥ Patients associations O Etampe Biomarkers, digital phenotyping, Algorithms *** île**de**France** Therapeutic strategies



FHU ADAPT, one step further towards Precision Medicine in Psychiatry

1.	2.	3.		5-
Building multimodal databases to identify homogenous clusters of patients with algorithms for patient stratification	Physiopathology underlying homogeneous subgroups of psychiatric/addiction disorders	New diagnostic tools and therapeutic strategies towards precision medicine	Development of a new French biomedical mental health sector, Incl. digital, biotech, medtech, pharma, medical devices etc.	Education, Implementation, attractiveness
TASK 1: Building multimodal databases (Clinical, genomics, metabolomics, immune, brain imaging, Ecological Momentary Assessment) towards biomarkers/algorithms for patient stratification (JF MANGIN, CEA & BTHIRION, INRIA)	TASK 2: Developing pre-clinical studies towards mechanisms discovery (J-A GIRAULT, Institut du Fer à Moulin, INSERM, & S GRANON, NEURO-PSI, CEA)	 TASK 3: Supporting clinical trials towards diagnostic tools and treatments discovery P LECORVOISIER & J HOUENOU (AP-HP & UPEC) E-health (A Pelissolo) Neurocognitive remediation (P Roux) Immuno–modulation (R Tamouza) Non invasive brain stimulation (C Laidi) Invasive brain stimulation (L Mallet) 	 TASK 4: Creating tools to develop a new biomedical sector (M LEBOYER AP-HP, UPEC, A REGNAULT, Université Paris Saclay) Plug in labs Tech meetings Patient registry Project support 	 TASK 5: Education and implementation (P VERNIER, CEA, A FAURE, Université Paris-Saclay) MD-PhD program Master classes Schools for residents University diploma in pharmaco- psychiatry Neuromodulation academy

• Biotherapies (S Palfi)

1. Building multimodal database to identify homogeneous clusters of patients

EXAMPLE of PROJECT: Stratification of psychotic patients based on blood-based inflammatory markers thanks to access to biological platforms which will then be validated by brain imaging (Pet Scan) AP-HP, MONDOR hospital (Créteil), CEA (Saclay), INRIA (Saclay), Inserm (Créteil), UPEC & Paris-Saclay University


1. Collecting biological markers of inflammation in existing cohorts



2. Stratifying inflammatory status using Machine Learning




3. Quantifying neuro-inflammation in high- and low-inflammatory subgroups by PET/MRI



2. Physiopathology underlying homogeneous subgroups of psychiatric/addiction disorders


EXAMPLE of PROJECT: Impact of perinatal exposure to air pollutants on neurodevelopmental psychiatric disorders (Schizophrenia and Autism) AP-HP, MONDOR hospital (Créteil), University Paris-Est-Créteil (Créteil), Inserm (Créteil), NeuroPsi Institute (Saclay)




3. New diagnostic tools and therapeutic strategies towards Precision Medicine

EXAMPLE of PROJECT: Non invasive brain stimulation in patients (autism and schizophrenia) selected with brain imaging **AP-HP, MONDOR hospital, Inserm, Neurospin (CEA, Saclay), University Paris-Est-Créteil**

- The cerebellum is altered in schizophrenia and autism (Laidi et al. 2015, 2017, 2019, in prep. ; Moberget et al. 2017)
- Step 1: Brain imaging study Identification of biomarkers of social withdrawal in a large database (ex: Healthy Brain Network – Child Mind Institute, NYC, n = 10 000)
- Step 2: Identification of patients included in the FondaMental database with altered cerebellar anatomy
- Step 3: Clinical trial on selected patients with autism and schizophrenia using cerebellar transcranial direct current stimulation (tDCS) targeting social withdrawal in autism and schizophrenia



Diedrichsen et al. 2015



Ferruci et al. 2015









4. Development of a new French biomedical mental health sector, Incl. digital, biotech, medtech, pharma, medical devices etc.

EXAMPLE of tools to enhance private/public partnerships

Paris-Est-Créteil University & Paris-Saclay University and Région Ile de France



 TECH
 MEETINGS

 by Université Paris-Saclay #TMUPSaclay



To detect opportunities for collaboration using a dedicated website describing each of the public/private FHU ADAPT laboratories' skills, expertise and technology



To organise meetings with short presentations, one-toone exchanges between SME, clinicians and researchers to boost collaboration



FHU ADAPT institutional partner: with the support of the Regional Council of Paris Ile-de-France





The Regional Council of Paris Ile-de-France is the local authority of the Paris Region, where all the partners of the FHU ADAPT are established. The regional authority identified:

- **Psychiatry** as a regional public health priority and as a major field for the social cohesion of the region and its economical development
- Saclay as one of its key economic and research areas

A strategic partnership between FHU ADAPT, FondaMental foundation and the regional council is being built in order to achieve its social and economic targets

The strategic partnership : a 3-year long program with identified operational actions

Psychiatry is an economic opportunity: building public-private partnerships

Economic forum on mental health in early 2020

Start-up challenge on mental health in 2020, with start-up cluster Medicen Psychiatry is an economic opportunity: building public-private partnerships

Regional communication plan on mental health

Financing research in psychiatry

5. Training the new generation of physicians and researchers in Psychiatry

MAIN OBJECTIVES:

- To disseminate innovation
- To increase national and international attractiveness

Paris-Est-Créteil University (UPEC) & Graduate School Life Science and Health of Paris-Saclay University EXAMPLES OF ACTIONS:

- Action 1: To increase training in research in Psychiatry for residents and MD-PhD
- Action 2: To develop Interdisciplinary symposium in psychiatry
- Action 3: To create a Neuromodulation Institute (Medtronic and Boston Scientific)
 - To teach the theory, techniques, and risks attached with neuromodulation
- Action 4: French School of Innovation in psychiatry
 - o Regulatory and ethical aspects, Project management methods and funding research












Key success factors of the FHU ADAPT to be followed



FHUADAPT ADdiction And Psychiatry TRANSFORMATION thanks to Precision Medicine

Marion Leboyer

AP-HP, DMU IMPACT, Hal H Mondor, Créteil University Paris-Est-Créteil (UPEC) INSERMU 955, IMRB, Translational NeuroPsychiatry lab, CEO Fondation FondaMental

Philippe Vernier

Director Neurosciences (Neuro-Psi) & Life Sciences Institutes CEA, Saclay

Jean-François Mangin Information Processing Unit, Neurospin, CEA, Saclay











